APA (7th ed.) Citation

Kim, H. R., Lee, S. J., Park, S., Jung, H. A., Lee, S., Jeong, H., . . . Ahn, M. (2022). A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer. Cancer Research & Treatment, 54(3), 719. https://doi.org/10.4143/crt.2021.1019

Chicago Style (17th ed.) Citation

Kim, Hye Ryeon, Su Jin Lee, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Han-Sin Jeong, Man Ki Chung, and Myung-Ju Ahn. "A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer." Cancer Research & Treatment 54, no. 3 (2022): 719. https://doi.org/10.4143/crt.2021.1019.

MLA (9th ed.) Citation

Kim, Hye Ryeon, et al. "A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer." Cancer Research & Treatment, vol. 54, no. 3, 2022, p. 719, https://doi.org/10.4143/crt.2021.1019.